AS03-adjuvanted H7N1 detergent-split virion vaccine is highly immunogenic in unprimed mice and induces cross-reactive antibodies to emerged H7N9 and additional H7 subtypes

Vaccine

Volumn 33, Issue 32, 2015, Pages 3784-3787

  Mallett, Corey P ^a   Beaulieu, Edith ^a   Joly, Marie Hélène ^a   Baras, Benoît ^b   Lu, Xiuhua ^c   Liu, Feng ^c   Levine, Min Z ^c   Katz, Jacqueline M ^c   Innis, Bruce L ^d   Giannini, Sandra L ^b  

^a GLAXOSMITHKLINE   (Canada)

^b GSK   (Belgium)

^c NATIONAL CENTER FOR IMMUNIZATION AND RESPIRATORY DISEASES   (United States)

^d GLAXOSMITHKLINE   (United States)

Author keywords

AS03 Adjuvant System; Avian H7 subtype influenza viruses; H7N1influenza vaccine; Unprimed mouse immunogenicity model

Indexed keywords

IMMUNOLOGICAL ADJUVANT; INACTIVATED VIRUS VACCINE; INFLUENZA VACCINE; INFLUENZA VIRUS HEMAGGLUTININ; VIRUS ANTIBODY; ALPHA TOCOPHEROL; ASO3B ADJUVANT; DRUG COMBINATION; INACTIVATED VACCINE; NEUTRALIZING ANTIBODY; POLYSORBATE; SQUALENE;

ADJUVANT THERAPY; ANIMAL EXPERIMENT; ANTIBODY BLOOD LEVEL; ANTIBODY RESPONSE; ANTIBODY TITER; ANTIGEN ANTIBODY REACTION; ARTICLE; CONTROLLED STUDY; CROSS REACTION; DOSE RESPONSE; HEMAGGLUTINATION INHIBITION; IMMUNOGENICITY; INFLUENZA A; INFLUENZA A (H7N1); INFLUENZA VACCINATION; INFLUENZA VIRUS A H3N2; INFLUENZA VIRUS A H5N1; INFLUENZA VIRUS A H7N1; INFLUENZA VIRUS A H7N3; INFLUENZA VIRUS A H7N7; INFLUENZA VIRUS A H7N9; MOUSE; NONHUMAN; PRIORITY JOURNAL; VIRION; ANIMAL; BLOOD; C57BL MOUSE; DRUG COMBINATION; FEMALE; HEMAGGLUTINATION INHIBITION TEST; IMMUNOLOGY; INFLUENZA A VIRUS (H7N1); INFLUENZA A VIRUS (H7N9); SERODIAGNOSIS;

ALPHA-TOCOPHEROL; ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; CROSS REACTIONS; DRUG COMBINATIONS; FEMALE; HEMAGGLUTINATION INHIBITION TESTS; INFLUENZA A VIRUS, H7N1 SUBTYPE; INFLUENZA A VIRUS, H7N9 SUBTYPE; INFLUENZA VACCINES; MICE, INBRED C57BL; NEUTRALIZATION TESTS; POLYSORBATES; SQUALENE; VACCINES, INACTIVATED;

EID: 84937519556     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2015.06.053     Document Type: Article

References (27)

1. Krauss S., Obert C.A., Franks J., Walker D., Jones K., Seiler P., et al. Influenza in migratory birds and evidence of limited intercontinental virus exchange. PLoS Pathog 2007, 3:e167.
2. Wallensten A., Munster V.J., Latorre-Margalef N., Brytting M., Elmberg J., Fouchier R.A.M., et al. Surveillance of influenza A virus in migratory waterfowl in northern Europe. Emerg Infect Dis 2007, 13:404-411.
3. Kang H.-M., Park H.-Y., Lee K.-J., Choi J.-G., Lee E.-K., Song B.-M., et al. Characterization of H7 influenza A virus in wild and domestic birds in Korea. PLoS ONE 2014, 9:e91887.
4. Hirst M., Astell C.R., Griffith M., Coughlin S.M., Moksa M., Zeng T., et al. Novel avian influenza H7N3 strain outbreak, British Columbia. Emerg Infect Dis 2004, 10:2192-2195.
5. Koopmans M., Wilbrink B., Conyn M., Natrop G., van der Nat H., Vennema H., et al. Transmission of H7N7 avian influenza A virus to human beings during a large outbreak in commercial poultry farms in the Netherlands. Lancet 2004, 363:587-593.
6. Fouchier R.A.M., Schneeberger P.M., Rozendaal F.W., Broekman J.M., Kemink S.A.G., Munster V., et al. Avian influenza A virus (H7N7) associated with human conjunctivitis and a fatal case of acute respiratory distress syndrome. Proc Natl Acad Sci USA 2004, 101:1356-1361.
7. Kurtz J., Manvell R.J., Banks J. Avian influenza virus isolated from a woman with conjunctivitis. Lancet 1996, 348:901-902.
8. Skowronski D.M., Tweed S.A., Petric M., Booth T., Li Y., Tam T. Human illness and isolation of low-pathogenicity avian influenza virus of the H7N3 subtype in British Columbia, Canada. J Infect Dis 2006, 193:899-900.
9. Lopez-Martinez I., Balish A., Barrera-Badillo G., Jones J., Nuñez-Garcia T.E., Jang Y., et al. Highly pathogenic avian influenza A (H7N3) virus in poultry workers, Mexico, 2012. Emerg Infect Dis 2013, 19:1531-1534.
10. Belser J.A., Tumpey T.M. Mammalian models for the study of H7 virus pathogenesis and transmission. Curr Top Microbiol Immunol 2014, 385:275-285.
11. Gao R., Cao B., Hu Y., Feng Z., Wang D., Hu W., et al. Human infection with a novel avian-origin influenza A (H7N9) virus. N Engl J Med 2013, 368:1888-1897.
12. Liu D., Shi W., Shi Y., Wang D., Xiao H., Li W., et al. Origin and diversity of novel avian influenza A H7N9 viruses causing human infection: phylogenetic, structural, and coalescent analyses. Lancet 2013, 381:1926-1932.
13. Li Q., Zhou L., Zhou M., Chen Z., Li F., Wu H., et al. Epidemiology of human infections with avian influenza A (H7N9) virus in China. N Engl J Med 2014, 370:520-532.
14. Belser J.A., Gustin K.M., Pearce M.B., Maines T.R., Zeng H., Pappas C., et al. Pathogenesis and transmission of avian influenza A (H7N9) virus in ferrets and mice. Nature 2013, 501:556-560.
15. Richard M., Schrauwen E.J.A., de Graaf M., Bestyebroer T.M., Spronken M.I.J., van Boheemen S., et al. Limited airborne transmission of H7N9 influenza A virus between ferrets. Nature 2013, 501:560-563.
16. ® cell grown influenza H7 virus vaccine. Vaccine 2009, 27:1889-1897.
17. Couch R.B., Patel S.M., Wade-Bowers C.L., Niño D. A randomized clinical trial of an inactivated avian influenza A (H7N7) vaccine. PLoS ONE 2012, 7:e49704.
18. Talaat K.R., Karron R.A., Callahan K.A., Luke C.J., DiLorenzo S.C., Chen G.L., et al. A live attenuated H7N3 influenza virus vaccine is well tolerated and immunogenic in a Phase I trial in healthy adults. Vaccine 2009, 27:3744-3753.
19. Rudenko L., Kiseleva I., Naykhin A.N., Erofeeva M., Stukova M., Donina S., et al. Assessment of human immune responses to H7 avian influenza virus of pandemic potential: results from a placebo-controlled, randomized, double-blind phase I study of live attenuated H7N3 influenza vaccine. PLoS ONE 2014, 9:e87962.
20. Babu T.M., Levine M., Fitzgerald T., Luke C., Sangster M.Y., Jin H., et al. Live attenuated H7N7 influenza vaccine primes for a vigorous antibody response to inactivated H7N7 influenza vaccine. Vaccine 2014, 32:6798-6804.
21. Fries L.F., Smith G.E., Glenn G.M. A recombinant viruslike particle influenza A (H7N9) vaccine. N Engl J Med 2013, 369:2564-2566.
22. Bart S.A., Hohenboken M., Della Cioppa G., Narasimhan V., Dormitzer P.R., Kanesa-thasan N. A cell culture-derived MF59-adjuvanted pandemic A/H7N9 vaccine is immunogenic in adults. Sci Transl Med 2014, 6:234ra55.
23. Baz M., Samant M., Zekki H., Tribout-Jover P., Plante M., Lanteigne A-M., et al. Effects of different adjuvants in the context of intramuscular and intranasal routes on humoral and cellular immune responses induced by detergent-split A/H3N2 influenza vaccines in mice. Clin Vaccine Immunol 2012, 19:209-218.
24. Baras B., Stittelaar K.J., Simon J.H., Thoolen R.J.M.M., Mossman S.P., Pistoor F.H.M., et al. Cross-protection against lethal H5N1 challenge in ferrets with an adjuvanted pandemic influenza vaccine. PLoS ONE 2008, 1:e1401.
25. De Vleeschauwer A.R., Baras B., Kyriakis C.S., Jacob V., Planty C., Giannini S.L., et al. Efficacy of an AS03A-adjuvanted split H5N1 influenza vaccine against an antigenically distinct low pathogenic H5N1 virus in pigs. Vaccine 2012, 30:5557-5563.
26. Krammer F., Albrecht R.A., Tan G.S., Margine I., Hai R., Schmolke M., et al. Divergent H7 immunogens offer protection from H7N9 challenge. J Virol 2014, 88:3976-3985.
27. Xu Q., Chen Z., Cheng X., Xu L., Jin H. Evaluation of live attenuated H7N3 and H7N7 vaccine viruses for their receptor binding preferences, immunogenicity in ferrets and cross reactivity to the novel H7N9 virus. PLoS ONE 2013, 10:e76884.